abioSCOPE® is able to early identify patients at high risk of sepsis, thanks to the combination of nanofluidic technologies and the detection of a potential sepsis biomarker: the Pancreatic Stone Protein (PSP).
PSP is an host protein biomarker for identification of patients at risk of infection-related organ dysfunction. It is produced mostly by the acinar cells of the pancreas and its blood level rises in the presence of a remote sepsis-related organ dysfunction.
PSP allows early identification of sepsis with high sensitivity and specificity.
The 5 minutes immunoassay test with PSP and abioSCOPE allows to identify sepsis as early as possible, in order to optimize selection and timing of the Antibiotic Treatment.